Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection)

Company
Orphan Medical

Approval Status
Approved October 1996

Treatment for
meningeal leukemia or lymphocytic lymphoma

Areas
Diabetes / Endocrinology , Cancer & Oncology

Elliotts B Solution has been approved as a treatment for meningeal leukemia or lymphocytic lymphoma. Leukemia and lymphomas are two of the main types of childhood cancers.

Adverse reactions may occur with any given intrathecal injection due to the chemotherapy or the technique of intrathecal administration.

Elliotts B Solution is comparable to cerebrospinal fluid in pH, electrolyte composition, glucose content, and osmolarity. Elliotts B Solution maintains the pH of methotrexate sodium and cytarabine closer to physiologic pH and provides a buffer capacity not found in other diluents, such as preservative-free saline.

Acute lymphocytic leukemia (ALL) is primarily a childhood leukemia, which accounts for approximately 57% of childhood leukemias. There are approximately 6,000 cases of ALL in the United States annually.

Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection) Drug Information

The Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top